Xiaoming Ming XuOrange, NJ

2022025, Aug 11, 2022

Sep 16, 2021

17/476656

- New York NY, US
Donald W. Landry - New York NY, US
Susan E. Bates - New York NY, US
Xiaoming Xu - Fair Lawn NJ, US

C07K 7/64
A61K 38/12
A61K 45/06

The present disclosure provides conjugate compositions comprising non-hydrolyzable, non-cleavable, stable linkers, a targeting moiety, and a therapeutic or chemotherapeutic agent. More specifically the present disclosure provides for compositions comprising non-hydrolyzable, non-cleavable, stable linkers, a somatostatin receptor (SSTR) targeting moiety, such as lanreotide, and a chemotherapeutic agent targeting microtubules, such as mertansine. Methods of using the compositions to treat cancer and other diseases are also provided.

2022021, Jul 7, 2022

May 7, 2020

17/608174

- FLORHAM PARK NJ, US
Xiaoming Xu - Edison NJ, US
Evan Vincent Miu - Chester NJ, US

BASF CORPORATION - FLORHAM PARK NJ

B01J 20/18
F01N 3/08
B01D 53/94
B01J 20/32
B01J 29/67
B01J 29/74

The present disclosure is directed to Low Temperature NOx-Absorber (LT-NA) catalyst compositions, catalyst articles, and an emission treatment system for treating an exhaust gas, each including the LT-NA catalyst compositions. Further provided are methods for reducing a NOlevel in an exhaust gas stream using the catalyst article. In particular, the LT-NA compositions include a zeolite containing a first metal component including palladium and a second metal component which is an alkaline earth metal component, an oxide of an alkaline earth metal component, a rare earth metal component, an oxide of a rare earth metal component, or a combination thereof. The LT-NA compositions exhibit increased low temperature NOadsorption capacity and enhanced hydrothermal stability.

2023009, Mar 23, 2023

Aug 24, 2022

17/894604

- New York NY, US
Shirong Li - Fort Lee NJ, US
Jing Fu - Fort Lee NJ, US
Donald W. Landry - New York NY, US
Shixian Deng - White Plains NY, US
Xiaoming Xu - Fair Lawn NJ, US

C07D 487/04

Compounds and methods for treatment of cancers such as multiple myeloma by inhibition of germinal center kinase.

2021021, Jul 15, 2021

May 29, 2019

17/250103

- Florham Park NJ, US
Evan Vincent MIU - Iselin NJ, US
Xiaoming XU - Iselin NJ, US
Xinyi WEI - Iselin NJ, US
Stefan MAURER - Shanghai, CN

BASF Corporation - Florham Park NJ

B01J 29/74
B01J 35/00
B01J 29/67
B01J 35/04
B01J 37/00
B01J 37/03
B01J 35/02
B01J 35/10
F01N 3/28
B01D 53/94

The present disclosure is directed to a Low Temperature NOx-Absorber (LT-NA) catalyst composition which exhibits NOx adsorption in a broad temperature and space velocity range, and shifts NOx desorption to a desired temperature range. In particular, the LT-NA composition includes a large pore zeolite containing a palladium component and a small or medium pore zeolite containing a palladium component. Further provided is a catalyst article including the LT-NA catalyst composition, an emission treatment system for treating an exhaust gas including the catalyst article, and methods for reducing a NOx level in an exhaust gas stream using the catalyst article.

2020016, May 28, 2020

Jul 31, 2018

16/633074

- New York NY, US
Xiaoming XU - Fair Lawn NJ, US
Thomas DIACOVO - Larchmont NY, US

The Trustees of Columbia University in the City of New York - New York NY

C07D 239/90
A61P 35/00
A61K 31/573
A61K 31/517
A61K 31/506
C07D 401/12
C07D 473/16
A61K 31/52
C07D 403/14

In an aspect, the disclosure provides for compounds (II), compositions, and methods of administering the compounds and compositions to a patient in need thereof. In another aspect, the disclosure relates to compounds and compositions for treating cancer, for example, lymphoid leukemia. The disclosure further provides for compounds which inhibit two phosphoinositide 3-kinase (PI3K) isoforms, y and δ, pharmaceutical compositions comprising said compounds, and methods of using said compounds and pharmaceutical compositions for treatment, amelioration, and/or prevention of non-Hodgkin lymphoma.

2019019, Jun 27, 2019

May 15, 2017

16/301352

- New York NY, US
Mark Lipstein - New York NY, US
Owen O'Connor - Scarsdale NY, US
Donald W. Landry - New York NY, US
Xiaoming Xu - Fair Lawn NJ, US
Xavier O. Jirau Serrano - Brooklyn NY, US

C07D 487/04
C07D 471/04
C07D 473/34
A61P 35/00

The invention relates to new compounds that reduce c-Myc expression and useful for cancer treatment, particularly hematological cancers such as aggressive B- and T-cell lymphomas. The new compounds may be combined with adjunct c-Myc inhibor agents such as a PI3K inhibitor, CK-1 inhibitor, Akt-inhibitor, proteasome inhibitor and/or mTor inhibitor. The c-Myc reducing agent may be provided as a lead-in treatment to reduce or initiate reduction of c-Myc prior to adminstration of the adjunct cancer therapeutic agent. Treatment with a c-Myc reducing agent modulates the disease state of the c-Myc overexpressing cancer making it less malignant and more susceptible to adjunctive cancer therapies.

2019007, Mar 7, 2019

Nov 4, 2016

15/773430

- New York NY, US
Donald W. Landry - New York NY, US
Mark Lipstein - New York NY, US
Michael Mangone - Brooklyn NY, US
Owen O'Connor - Scarsdale NY, US
Xavier O. Jirau Serrano - Brooklyn NY, US
Luigi Scotto - Stamford CT, US
Xiaoming Xu - Fair Lawn NJ, US

A61K 31/52
A61K 31/551
A61P 9/10
A61P 35/02
A61K 31/336
A61K 31/5375

The invention relates to the co-administration of select proteasome and PI3K inhibitors is useful for treating c-Myc-overexpressing cancers, particularly hematological cancers such as aggressive B- and T-cell lymphomas. In exemplified embodiments, coadministration of a dual PI3K/CK-1 inhibitor with a proteasome inhibitor synergistically increases cell death of aggressive B- and T-cell lymphomas as well as multiple myeloma over the individual or additive effect of either or both agents. This synergistic effect is associated with the previously unknown inhibition of the kinase casein kinase 1 epsilon (CK-1ε) by a PI3K inhibitor, such as TGR-1202. Accordingly, use of PI3K inhibitors that possess CK-1ε inhibition in combination with proteasome inhibitors provides a new therapy regime for treating c-Myc-overexpressing cancers, and particularly hematological cancers.

2019001, Jan 17, 2019

Jan 5, 2017

16/068418

- Florham Park NJ, US
Xiaoming XU - Edison NJ, US
Stanley ROTH - Yardley PA, US

B01D 53/94
B01J 23/42
B01J 35/00
B01J 35/04
F01N 3/10

The present invention relates to diesel oxidation catalyst compositions and catalyst articles, wherein the compositions and articles include a plurality of platinum group nanoparticles substantially in fully reduced form, wherein the nanoparticles have an average particle size of about 1 to about 10 nm and at least about 90% of the nanoparticles have a particle size of +/− about 2 nm of the average particle size. Such compositions can further include a refractory metal oxide material, wherein the nanoparticles and refractory metal oxide material can be combined within the same coating on a substrate or can be applied sequentially on a substrate. The nanoparticles can advantageously be substantially free of halides, alkali metals, alkaline earth metals, sulfur compounds, and boron compounds. Methods of preparing and using such compositions and catalyst articles (e.g., for the treatment of diesel exhaust gas streams) are also provided herein.